Research & Development Centres near Pinware NL (103 Result(s))

LinksNexus Clinical Research was founded in 2004 by Dr. Ian Landells, a leading dermatologist, and Dr. Majed Khraishi, a leading rheumatologist.Nexus Clinical Research operates with the mandate to 'provide tomorrow's therapies today', employing internationally leading standards to benefit the health of both the people of Newfoundland-Labrador and the people of the world.News Release:

The Health Research Ethics Authority Act (The Act) came into force on July 1, 2011. The Act can be viewed here. The regulation governing review of clinical trials and genetics research can be found here.The Act will require that all health research done in the province be reviewed and approved by a local (Newfoundland and Labrador) research ethics review board. The Health Research Ethics Authority (HREA) oversees ethics review of health research by the Health Research Ethics Board (HREB) or an approved health research ethics review body.

Oceans Research provides and facilitates innovative and dynamic research relevant to the management and conservation of Southern Africa's wildlife.Its research is interdisciplinary ranging from biological to socio-economic studies of marine and terrestrial resource utilisation in Southern Africa's coastal society. Oceans Research specialises in investigating the biology and ecology of mega-fauna, including sharks, marine mammals and terrestrial carnivores; we advise governmental and non-governmental bodies on relevant conservation issues.

MBRC is defined as a vocation for research and development (R & D) oriented and applied as well as services industrial biotechnology research . MBRC acts as an intermediary organization and stowage between academic institutions and private companies by pr

Kytogenics Pharmaceuticals, Inc. is a drug delivery and medical products company moving forward to develop and market a series of clinically significant therapies and products based on its N,O- carboxymethylchitosan (NOCC) chitosan derived technology and its sulfated derivative s-NOCC. Through the FDA 510K process Kytogenics has successfully cleared one product for marketing in its wound care/derma line, its NOCC Hydrophilic Wound Dressing, and the Company is developing additional diverse and innovative products lines based on its NOCC and s-NOCC Technology platforms and expects products on the market within one year. Wound care and orthopedic products are in the project stage of commercialization. Using the Companys chitosan derivatives, Kytogenics intends to develop a significant opportunity for topically applied drug delivery initially with rewetting/lubricating drops for lenses and artificial tears, followed by retinal/vitreous delivery. Therapeutic products for Interstitial Cystitis and Inflammatory Bowel Disease are among Kytogenics development programs and the Company has successfully applied its technology to the delivery of peptides and other macromolecules and more recently for drug delivery to mucosal tissues.